

ESTIMATED ANNUALIZED BURDEN TABLE OVER THREE YEARS

Type of respondent	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden hours
Private sector companies, SLTT, Trade groups and associations, NGOs, Manufacturers, distributors, Academia, Healthcare delivery providers/facilities, Public, USG Supply chain inventory holders, Biopharmaceutical industry, Biotechnology development companies, Communities, GPOs, standards development organizations, logistics, third party contractors, purchasing organizations, professional associations/societies, Mixed cross-sector audience, labor unions, workforce training providers, organizations, state and local workforce boards, and individuals who rely on wearable medical countermeasures.	Informed consent	32,800	1	0.08	2,624
	Demographics standardized questionnaire with decision logic allowing some questions to be omitted.	32,800	1	0.25	8,200
	Cognitive questionnaire	5,990	1	8	47,920
	Formative interviews and focus groups.	6,600	2	4	52,800
	Town halls and public meetings	10,200	2	8	163,200
	Supply chain questionnaires	1,000	156	0.5	78,000
	Knowledge-based questionnaires ..	6,000	1	0.5	3,000
	Interviews and focus groups	3,000	1	1	3,000
	Instrumented information collection	160	1	0.5	80
Total Burden Hours Over Three Years					358,824

Catherine Howard,

Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary

[FR Doc. 2026-03919 Filed 2-26-26; 8:45 am]

BILLING CODE 4150-37-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders.

Date: March 31, 2026.

Time: 8:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Gagan Deep Bajaj, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of

Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594-7377, gagan.bajaj@nih.gov.

Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Biobehavioral Mechanisms of Emotion, Stress and Health Study Section.

Date: March 31, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Brittany I. Mason-Mah, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000A, Bethesda, MD 20892, (301) 594-3163, masonmahbl@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Cancer Immunology and Immunotherapy II.

Date: April 1, 2026.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Hasan Siddiqui, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, Bethesda, MD 20817, (301) 451-0395, hasan.siddiqui@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Hepatology, Toxicology, and Xenobiotic Metabolism and Disposition.

Date: April 1, 2026.

Time: 9:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Charlene J. Repique, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594-8858, charlene.repique@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Projects: Cardiovascular Biology and Hematology.

Date: April 1, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Manoj Kumar Valiyaveetil, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 402-1616, manoj.valiyaveetil@nih.gov.

Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Pathophysiology of Eye Disease—2 Study Section.

Date: April 1–2, 2026.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Barbara Susanne Mallon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-8992, mallonb@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Medical Imaging Research.

Date: April 1, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Debanjan Goswami, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Office 810-G, Bethesda, MD 20892, (301) 451-1587, debanjan.goswami@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Maximizing Investigators' Research Award (R35).

Date: April 1–2, 2026.

Time: 9:30 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Mufeng Li, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 507-9155, mufeng.li@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR-25-447: NHLBI TOPMed—Omics Phenotypes of Heart, Lung, and Blood Disorders.

Date: April 1, 2026.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Dharmendar Rathore, MSC, BSC, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892 (301) 496-6431, dharmendar.rathore@nih.gov.

Name of Committee: Emerging Technologies and Training Neurosciences Integrated Review Group Molecular Neurogenetics Study Section.

Date: April 2–3, 2026.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Prithi Rajan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594-8206, prithi.rajan@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 24, 2026.

Bruce A. George,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-03913 Filed 2-26-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Board of Scientific Counselors of the NIH Clinical Center, March 16, 2026, 10:00 a.m. to March 17, 2026, 12:30 p.m., National Institutes of Health, Clinical Center, 10 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on January 12, 2026, 91 FR 1192.

This notice is being amended due to a change in Designated Federal Officer (DFO). Ms. Julie Goldberg will be the new DFO and point of contact for this meeting. The agenda will remain the same. This meeting is closed to the public.

Dated: February 24, 2026.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-03908 Filed 2-26-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Powered Gait Assistance Systems and Gait Assistance Systems and Methods of Control Thereof

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The Clinical Center of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to Bionic Power Inc., a company organized in British Columbia, Canada.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 16, 2026 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Edward Fenn, Senior

Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-6833; Email Tedd.Fenn@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

1. US Provisional Patent Application No. 62/368,926 filed July 29, 2016, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-01];

2. International PCT Application No. PCT/US2017/044625 filed July 31, 2017, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-PCT-02];

3. US Patent No. 11,801,153 issued 10/31/2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-03];

4. US Patent Application No. 18/243,573, filed 9/7/2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-04];

5. US Provisional Patent Application No. 63/539,898 filed September 22, 2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-241-2023-0-US-01];

6. International PCT Application No. PCT/US2024/047743 filed September 20, 2024, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-241-2023-PCT-02];

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide where patent rights exist and the field of use may be limited to the following:

"For the treatment of human movement disorders."

The subject technologies relate to systems, methods, and devices for powered gait assistance—that may be integrated to comprise a wearable orthosis (for example a powered exoskeletal device) that attaches to the leg of a user who has a movement disorder, such as a gait disorder. The technologies can augment and provide assistance and training for improvements to walking. The system can detect movements, such as gait phases and adjust torque in real time to provide assistive torque during stance and resistive torque during training to improve strength and movement mechanics of the user. For example, it can provide assistance with gait movement for patients with knee extension deficits in conditions such as crouch gait in cerebral palsy, or spina bifida, stroke and other movement disorders).